Jane Osbourn is chief scientific officer at Alchemab Therapeutics, where she focuses on understanding the immunological basis of disease resilience and identifying protective antibodies as therapies for neurodegeneration. She was an early employee of Cambridge Antibody Technology, which became MedImmune (the biologics arm of AstraZeneca), where she authored numerous key publications and patents and contributed to the discovery and development of eight marketed drugs. Dr. Osbourn is passionate about the development of the biotechnology sector and she chaired the UK BioIndustry Association (BIA) from 2015 to 2019. She is the chair of Mogrify, a Cambridge-based cell-therapy company and a founder of RQ Bio, a UK-based infectious disease company. In 2019, she received an OBE for services to drug discovery and biotechnology and the Scrip Lifetime Achievement Award for contributions to the pharmaceutical industry. In 2023, she received the BIA Lifetime achievement award, recognizing her sustained contribution to biologics drug development.